Pfizer Vaccine by Pfizer and its German partner BioNTech works on Kids age 5-11 according to Pfizer itself. Early results of their trial indicate the vaccine is safe for children and establishes a strong antibody response against the covid-19 virus.
Yes, we are moving further in our efforts of going back to our normal lives and leave this pandemic behind. While kids are known to be at a lower risk of severe illness or death than older people, the schools are slowly being opened to face-to-face classes which calls for the younger kids protection as soon as possible.
Pfizer said it studied the lower dose, for safety and effectiveness, in 2,268 kids in kindergarten and elementary. Giving a two-dose regimen of 10 micrograms administered 21 days apart, the shot was well tolerated according to both pharmaceutical companies.
This trial used a smaller vaccine dosage, 1/3 of the 30-microgram dose used for older people.
It is not a scientific publication but is called an immune “bridging” study. It seeks to provide evidence that the younger children developed antibody levels already proven to be protective in teens and adults.
After their second dose, the children developed coronavirus-fighting antibody levels just as strong as teenagers and young adults.
Known similar or fewer temporary side effects are:
- Sore arms
The study is still ongoing but once analysis of the trial is completed, Pfizer and BioNTech will submit the results to the Food and Drug Administration in US for review and possible emergency use authorization.
As the study is not yet completed and taking into consideration the authorizations from different sectors among different countries after their initial review to be requested, it would likely be available by the end of 2021 or early 2022.
Pfizer and Moderna are also currently studying even younger ones, toddlers in fact, down to 6-month-olds. Results are expected to come later in the year though.